Jove
Visualize
Contact Us

Related Experiment Videos

Interferon beta: the current position

B R Boothman1

  • 1Department of Neurology, Royal Preston Hospital.

British Journal of Hospital Medicine
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

New multiple sclerosis treatments are available, but long-term disability effects remain unknown. Interferon beta trials showed no significant disability reduction, questioning its prescription for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation.

Neurology·2005
Same author

A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy.

Seizure·2005
Same author

Transient myoclonus after exposure to oven cleaner.

Movement disorders : official journal of the Movement Disorder Society·1991
Same author

Pharmacokinetic data for ropinirole.

Lancet (London, England)·1990
Same author

Paraplegia as a presenting feature of meningococcal meningitis.

Journal of neurology, neurosurgery, and psychiatry·1988
Same author

Problems with anticoagulants.

British medical journal (Clinical research ed.)·1982
Same journal

The autopsy in the 1990s.

British journal of hospital medicine·1999
Same journal

Screening for breast cancer.

British journal of hospital medicine·1999
Same journal

Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension.

British journal of hospital medicine·1999
Same journal

Liposarcoma: a review of current diagnosis and management.

British journal of hospital medicine·1999
Same journal

How to do it in surgery: laparoscopic rectopexy.

British journal of hospital medicine·1999
Same journal

The management of ovarian cancer.

British journal of hospital medicine·1999
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Available multiple sclerosis (MS) treatments aim to reduce disease activity.
  • The long-term impact of these disease-modifying therapies on disability progression in MS is not yet understood.

Purpose of the Study:

  • To evaluate the long-term efficacy of available treatments in modifying disability accumulation in multiple sclerosis.
  • To assess whether findings from interferon beta trials warrant continued prescription.

Main Methods:

  • Review of published clinical trials focusing on disease-modifying therapies for multiple sclerosis.
  • Analysis of data regarding disability accumulation in patients undergoing treatment.

Main Results:

Related Experiment Videos

  • Published trials utilizing interferon beta did not demonstrate a clinically significant reduction in the accumulation of disability during the study periods.
  • Current evidence does not confirm a long-term benefit of interferon beta on disability progression in multiple sclerosis.

    • Conclusions:

    • The long-term effect of current multiple sclerosis treatments on disability progression requires further investigation.
    • The clinical utility of interferon beta in preventing long-term disability accumulation in multiple sclerosis remains uncertain based on available trial data.